Sign in →

Test Code IFG23 Intact Fibroblast Growth Factor 23, Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Useful For

Diagnosing and monitoring tumor induced osteomalacia

 

Diagnosing X-linked hypophosphatemia or autosomal dominant hypophosphatemic rickets

 

Diagnosing familial tumoral calcinosis with hyperphosphatemia

Method Name

Chemiluminescence-Based Quantitative Sandwich Immunoassay

Reporting Name

Intact Fibroblast Growth Factor 23

Specimen Type

Serum

Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 14 days
  Frozen  90 days

Reference Values

Pediatric (<18 yrs): ≤52 pg/mL

Adults (≥18 yrs): ≤ 59 pg/mL

Interpretation

Increased fibroblast growth factor 23 (FGF23) concentrations are present in individuals with renal phosphate-wasting diseases such as autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), X-linked hypophosphatemia rickets (XLH) and tumor induced osteomalacia (TIO). Clinically, FGF23 measurement is useful in the differential diagnosis of these hypophosphatemic diseases since the patient presents with high FGF23 levels along with hypophosphatemia. In other causes of hypophosphatemia, such as vitamin D deficiency, FGF23 levels are low. In FGF23-producing tumors, a decrease in FGF23 concentrations following surgery is a reliable indication of complete tumor resection.

 

Intact FGF23 concentrations are elevated in patients with TIO or XLH. However, intact FGF23 concentrations within the reference interval do not exclude the disease and should be interpreted in the setting of phosphate concentrations (ie, an FGF23 concentration in the upper level of the reference interval in the context of hypophosphatemia might be indicative of XLH). In ADHR, FGF23 concentrations are not consistently elevated, and the severity of renal phosphate-wasting may wax and wane; FGF23 concentrations are normal during quiescent periods when serum phosphate levels are normal, and they are elevated during active, hypophosphatemic phases of the disease.(1) FGF23 concentrations are influenced by factors such as phosphate intake and vitamin D therapy. Therefore, intact FGF23 levels are most informative in untreated patients.

 

In the setting of hypophosphatemia, an elevated FGF23 may be indicative of FGF23-mediated hypophosphatemia. In a Mayo Clinic study, using the Medfrontier (Minaris Medical Co, Ltd, Tokyo, Japan) and a cut-off of greater than or equal to 59 pg/mL, corresponding to the upper limit of the reference interval, intact FGF23 concentrations were elevated in 90% and 84% of TIO and XLH hypophosphatemia patients, respectively. In the TIO and XLH patients where the intact FGF23 concentration was not above the reference interval, the intact FGF23 concentrations were at the upper end of the reference interval and much higher than observed in the patients with FGF23-independent hypophosphatemia. In contrast in the patients with FGF23-independent hypophosphatemia, intact FGF23 concentrations were significantly lower than what was observed in the healthy cohort and the normophosphatemic patients.(2) A study using the same assay and a cut-off of 30.0 pg/mL, reported 100% sensitivity and 82% specificity for the differential diagnosis of FGF23-related hypophosphatemia rickets/osteomalacia without vitamin D deficiency versus non-FGF23-related hypophosphatemia.(3)

Clinical Reference

1. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007;22(4):520-526

2. Ramos P, Larson B, Ashrafzadeh-Kian S, et al. Intact fibroblast growth factor 23 concentrations in hypophosphatemic disorders. Endocr Pract. 2023;29(3):193-198. doi:10.1016/j.eprac.2023.01.003

3. Ito, N., Kubota, T., Kitanaka, S.et al. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23. J Bone Miner Metab. 2021;39(6):1066-1075.doi.org/10.1007/s00774-021-01250-1

4. Ashrafzadeh-Kian SL, Ito N, Srivastava T, el al. The effect of burosumab on intact and C-terminal FGF23 measurements. Clin Endocrinol (Oxf). 2023;99(2):152-157. doi:10.1111/cen.14832

5. Imel EA, Gray AK, Padgett LR, Econs MJ. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone. 2014;60:87-92

6. Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphatemia. Nat Rev Nephrol. 2019;15(7):435-455. doi:10.1038/s41581-019-0152-5

7. Fauconnier C, Roy T, Gillerot G, Roy C, Pouleur AC, Gruson D: FGF23: Clinical usefulness and analytical evolution. Clin Biochem. 2019;66:1-12. doi:10.1016/j.clinbiochem.2019.03.002

8. Hartley IR, Gafni RI, Roszko KL, et al. Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia. J Bone Miner Res. 2022;37(11):2174-2185. doi:10.1002/jbmr.4702

Day(s) Performed

Tuesday, Thursday

Report Available

2 to 8 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

83520

LOINC Code Information

Test ID Test Order Name Order LOINC Value
IFG23 Intact Fibroblast Growth Factor 23 54390-0

 

Result ID Test Result Name Result LOINC Value
607216 Intact Fibroblast Growth Factor 23 54390-0

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

Renal Diagnostics Test Request (T830)

Oncology Test Request (T729)